Editor's Note: In May 2013, the US Food and Drug Administration (FDA) approved Liptruzet™ (ezetimibe and atorvastatin) for the treatment of elevated low-density lipoprotein (LDL) cholesterol levels in ...
LIPTRUZET (ezetimibe and atorvastatin) tablets The FDA has approved Liptruzet, combination of ezetimibe and atorvastatin, for the treatment of elevated LDL cholesterol in patients with primary or ...
Forbes: The FDA Approval Of Merck's Cholesterol Lowerer, Liptruzet, Doesn't Help Its Credibility
The FDA Approval Of Merck's Cholesterol Lowerer, Liptruzet, Doesn't Help Its Credibility
Post and Courier: Merck recalls entire supply of combo cholesterol drug Liptruzet
TRENTON, N.J. -- Drugmaker Merck & Co. said Tuesday that it’s recalling Liptruzet, a combination cholesterol drug, wiping out the entire U.S. stock, due to packaging defects that could reduce ...
FiercePharma: Merck Voluntarily Recalls All Lots of LIPTRUZET™ in the United States From Wholesalers Due to Packaging Defects
WHITEHOUSE STATION, N.J., Merck (NYSE: MRK), known as MSD outside the United States and Canada, is voluntarily recalling all lots of LIPTRUZET™ (ezetimibe and atorvastatin) 10/10 mg, 10/20 mg, 10/40 ...
Merck Voluntarily Recalls All Lots of LIPTRUZET™ in the United States From Wholesalers Due to Packaging Defects
MM&M: Merck’s Liptruzet may mend IMPROVE-IT, but offers little in the short run
The approval of Merck’s new cholesterol lowering combo drug Liptruzet (Zetia-plus-atorvastatin) has been met with raised eyebrows. Newly approved Liptruzet boasts market-leading efficacy. In studies, ...
Merck’s Liptruzet may mend IMPROVE-IT, but offers little in the short run
Pharmabiz: Merck’s Liptruzet receives US FDA approval for treatment of LDL cholesterol
The US Food and Drug Administration (FDA) has approved Merck's Liptruzet (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with ...